RT Journal Article
T1 The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study
A1 Gomez-Acebo, Ines
A1 Dierssen-Sotos, Trinidad
A1 Palazuelos, Camilo
A1 Perez-Gomez, Beatriz
A1 Lope, Virginia
A1 Tusquets, Ignasi
A1 Henar Alonso, M.
A1 Moreno, Victor
A1 Amiano, Pilar
A1 Jose Molina de la Torre, Antonio
A1 Barricarte, Aurelio
A1 Tardon, Adonina
A1 Camacho, Antonio
A1 Peiro-Perez, Rosana
A1 Marcos-Gragera, Rafael
A1 Munoz, Montse
A1 Jesus Michelena-Echeveste, Maria
A1 Ortega Valin, Luis
A1 Guevara, Marcela
A1 Castano-Vinyals, Gemma
A1 Aragones, Nuria
A1 Kogevinas, Manolis
A1 Pollan, Marina
A1 Llorca, Javier
K1 Calcium-channel blockers
K1 Cohort
K1 Women
K1 Apoptosis
K1 Mortality
K1 Carcinoma
AB IntroductionThe evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers.MethodsIn this case-control study, we report the antihypertensive drugs-breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women's characteristics (i.e., menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs.ResultsThe relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the OR increased significantly in the group with BMI >= 25 (OR 2.54, 95% CI, 1.24 to 5.22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to 9.05; OR for Erbb2+cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk.ConclusionsIn this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women).
PB Public library science
SN 1932-6203
YR 2016
FD 2016-08-10
LK http://hdl.handle.net/10668/19151
UL http://hdl.handle.net/10668/19151
LA en
DS RISalud
RD Apr 4, 2025